IgG3-Factor VII Immunoconjugates Targeting Tissue Factor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to specifically target and eliminate tissue factor-expressing angiogenic vascular endothelial cells and cancer cells, which are involved in various pathological conditions such as cancer, rheumatoid arthritis, and macular degeneration, often resulting in inadequate treatment outcomes and drug resistance.
Innovation Solution
Development of immunoconjugate proteins, specifically third and fourth-generation tissue factor-targeting ICONs (L-ICON3 and ICON4), comprising an Fc region of IgG3 or hybrid IgG1/IgG3 conjugated to Factor VII, designed to initiate stronger antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity without pro-coagulation activity, for targeted therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used to treat tissue factor-expressing cells, then treatment coverage is broad, but specificity and effectiveness are insufficient leading to drug resistance
Solution Approach 1:
The therapy is segmented into two distinct functional components: a targeting moiety (Factor VII or its fragments) that specifically binds to tissue factor-expressing cells, and an effector moiety (IgG3 Fc region) that mediates cytotoxicity. This segmentation allows the conjugate to selectively target only TF-expressing cells while leaving normal cells unaffected, thereby improving treatment effectiveness and eliminating drug resistance through precise molecular targeting rather than broad-spectrum therapy
Solution Approach 2:
The immunoconjugate acts as an intermediary molecule that bridges the gap between the targeting function (recognizing TF on cancer cells) and the effector function (inducing ADCC and CDC). The Factor VII portion serves as the targeting intermediary that binds to TF, while the IgG3 Fc region serves as the effector intermediary that recruits immune cells and activates complement, thereby translating specific binding into selective cell destruction without affecting non-target cells
2Duration of action of stationary object
If IgG1 Fc region is used in immunoconjugates, then half-life is extended, but ADCC activity is insufficient
Solution Approach 1:
The invention changes the key parameter of the Fc region from IgG1 to IgG3, which fundamentally alters the biological properties of the immunoconjugate. IgG3 has inherently higher affinity for FcγRIIIa on NK cells, resulting in significantly enhanced ADCC activity. The parameter change also affects serum half-life, which is then optimized through additional modifications such as FcRn binding enhancement or PEGylation to achieve both high ADCC potency and adequate circulation time
Solution Approach 2:
The immunoconjugate employs a composite structure combining the targeting domain (Factor VII) with the effector domain (IgG3 Fc region). This composite design leverages the unique properties of IgG3—its superior ADCC capability due to higher FcγRIIIa binding affinity—while maintaining the targeting specificity of Factor VII. The composite structure allows simultaneous optimization of both ADCC activity and pharmacokinetic properties through rational design of each component
3Measurement precision
If Factor VII is used for targeting, then specificity to tissue factor is high, but pro-coagulation activity causes harmful side effects
Solution Approach 1:
The invention extracts only the essential targeting function of Factor VII by using the light chain portion or truncated versions that retain TF binding capability but lack the pro-coagulation activity. By removing the harmful coagulation-inducing domains while preserving the binding interface, the design achieves high targeting specificity without the dangerous side effect of activating the coagulation cascade, thereby preventing thrombotic complications
Solution Approach 2:
The invention converts the potential harm of Factor VII's pro-coagulation activity into a benefit by utilizing the natural high-affinity binding between Factor VII and Tissue Factor as the targeting mechanism, while deliberately eliminating the downstream coagulation activation. The specific binding interaction, which normally leads to coagulation, is harnessed purely for targeting purposes, and the harmful coagulation cascade is blocked by using truncated forms that cannot activate Factor X, thus turning the strong TF-FVII interaction into a safe and effective targeting tool
4Productivity
If broad-spectrum chemotherapy is used, then all cancer cells are targeted, but healthy cells are damaged and treatment resistance develops
Solution Approach 1:
The therapy is segmented into two distinct functional components: a targeting moiety (Factor VII or its fragments) that specifically binds to tissue factor-expressing cells, and an effector moiety (IgG3 Fc region) that mediates cytotoxicity. This segmentation allows the conjugate to selectively target only TF-expressing cells while leaving normal cells unaffected, thereby improving treatment effectiveness and eliminating drug resistance through precise molecular targeting rather than broad-spectrum therapy
Solution Approach 2:
The immunoconjugate acts as an intermediary molecule that bridges the gap between the targeting function (recognizing TF on cancer cells) and the effector function (inducing ADCC and CDC). The Factor VII portion serves as the targeting intermediary that binds to TF, while the IgG3 Fc region serves as the effector intermediary that recruits immune cells and activates complement, thereby translating specific binding into selective cell destruction without affecting non-target cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These immunoconjugates demonstrate enhanced binding and cytotoxic effects on cancer cells, effectively treating various solid cancers, rheumatoid arthritis, and other diseases by selectively targeting tissue factor-expressing cells, offering improved therapeutic potential with reduced side effects.
Implementation Method 1
designed to initiate stronger antibody-dependent cell-mediated cytotoxicity
Implementation Method 2
complement-dependent cytotoxicity without pro-coagulation activity
Data Source
AI summary
Disclosed are methods and compositions related to immunoconjugates. Particularly disclosed are immunoconjugates that comprise the Fc portion of IgG3 as well as Factor VII light chain or Factor VII. Also disclosed is an immunoconjugate protein, wherein said immunoconjugate protein comprises a hybrid Fc region of an IgG1 and an IgG3 immunoglobulin conjugated to Factor VII. These immunoconjugates can target Tissue Factor (TF) expressing cells.